Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation.
暂无分享,去创建一个
G. Guyatt | D. Cook | R. Jaeschke | D. Cook | M. Newhouse | Roman Jaeschke | A. Willan | J. Morris | S. Harper | H. Ramsdale | R. Haddon | A. Willan | M. Newhouse | G. Guyatt | Sandi Harper | Joanne Morris | Roger Haddon
[1] W. McIlroy,et al. The effect of increasing doses of beta-agonists on airflow in patients with chronic airflow limitation. , 1993, Respiratory Medicine.
[2] Guidelines for the assessment and management of chronic obstructive pulmonary disease. Canadian Thoracic Society Workshop Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[3] A. Verbeek,et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. , 1991, BMJ.
[4] C. Madden. Regular inhaled beta-agonist treatment in bronchial asthma , 1991 .
[5] G. Guyatt,et al. Mechanism of bronchodilator effect in chronic airflow limitation. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[6] B. Lipworth,et al. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.
[7] G H Guyatt,et al. The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. , 1990, Annals of internal medicine.
[8] N. Anthonisen,et al. Tolerance to ß2-Agonists in Patients with Chronic Obstructive Pulmonary Disease , 1990 .
[9] C. McDonald,et al. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. , 1989, Chest.
[10] G. Guyatt,et al. Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.
[11] P. Rees,et al. Maximum achievable bronchodilatation in asthma. , 1989, Respiratory medicine.
[12] M. Aubier,et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. , 1989, The New England journal of medicine.
[13] P. Munzenberger,et al. A clinical comparison of terbutaline with albuterol administered by metered-dose inhaler. , 1989, Annals of allergy.
[14] M. Hodson,et al. High dose salbutamol in chronic airflow obstruction: comparison of nebulizer with Rotacaps. , 1989, Respiratory medicine.
[15] J. Britton,et al. High-dose inhaled albuterol in severe chronic airflow limitation. , 1988, The American review of respiratory disease.
[16] G. Guyatt,et al. A clinician's guide for conducting randomized trials in individual patients. , 1988, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[17] G. Guyatt,et al. A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.
[18] J. Moxham,et al. High dose salbutamol in chronic bronchitis: Comparison of 400 μg, 1 mg, 1.6 mg, 2 mg and placebo delivered by Rotahaler , 1987 .
[19] G. Mchardy,et al. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. , 1987, Thorax.
[20] J. Moxham,et al. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. , 1987, Chest.
[21] H. D. Short,et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. , 1987, The American review of respiratory disease.
[22] C. Connolly,et al. Salbutamol and ipratropium in partially reversible airway obstruction. , 1987, British journal of diseases of the chest.
[23] G. Torrance. Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.
[24] J A Smyth,et al. Determining optimal therapy--randomized trials in individual patients. , 1986, The New England journal of medicine.
[25] C. Wells,et al. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. , 2015, The American review of respiratory disease.
[26] R. Gilbert. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. , 1985, The American review of respiratory disease.
[27] D. Postma,et al. Severe chronic airflow obstruction: can corticosteroids slow down progression? , 1985, European journal of respiratory diseases.
[28] D. Taylor,et al. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. , 1985, The American review of respiratory disease.
[29] M. Leslie,et al. Short term variability in FEV1: relation to pretest activity, level of FEV1, and smoking habits. , 1984, Thorax.
[30] G H Guyatt,et al. Effect of encouragement on walking test performance. , 1984, Thorax.
[31] D. Mitchell,et al. EFFECTS OF PREDNISOLONE IN CHRONIC AIRFLOW LIMITATION , 1984, The Lancet.
[32] C. Kelly,et al. Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation. , 1984, Thorax.
[33] R. Kaplan,et al. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. , 1984, Journal of chronic diseases.
[34] P. Corris,et al. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. , 1983, Thorax.
[35] C. Kelly,et al. ASSESSMENT OF THE CLINICAL USEFULNESS OF NEBULIZED IPRATROPIUM BROMIDE WITH CHRONIC AIR-FLOW LIMITATION , 1983 .
[36] J. Prior,et al. Assessment of optimum dose of inhaled terbutaline in patients with chronic asthma: the use of simple, cumulative dose-response curves. , 1982, British journal of diseases of the chest.
[37] S. Freedman,et al. A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response. , 1978, Thorax.
[38] N. Svedmyr,et al. Evaluation of skeletal muscle tremor due to bronchodilator agents. , 1975, Scandinavian journal of respiratory diseases.
[39] Fluorocarbon Aerosol Propellants , 1975, The Lancet.
[40] B. Simonsson,et al. Double-blind trial with increasing doses of salbutamol and terbutaline aerosols in patients with reversible airways obstruction. , 2009, Acta medica Scandinavica.
[41] B. Freedman. Trial of a terbutaline aerosol in the treatment of asthma and a comparison of its effects with those of a salbutamol aerosol. , 1972, British journal of diseases of the chest.